story of the week
Palbociclib in Combination With Endocrine Therapy vs Capecitabine in HR-Positive, HER2-Negative, Aromatase Inhibitor–Resistant Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Palbociclib in Combination With Endocrine Therapy Versus Capecitabine in Hormonal Receptor-Positive, Human Epidermal Growth Factor 2-Negative, Aromatase Inhibitor-Resistant Metastatic Breast Cancer: A Phase III Randomised Controlled Trial – PEARL
Ann. Oncol 2020 Dec 29;[EPub Ahead of Print], M Martin, C Zielinski, M Ruiz-Borrego, E Carrasco, N Turner, EM Ciruelos, M Muñoz, B Bermejo, M Margeli, A Anton, Z Kahan, T Csöszi, MI Casas, L Murillo, S Morales, E Alba, E Gal-Yam, A Guerrero-Zotano, L Calvo, J Haba-Rodriguez, M Ramos, I Alvarez, A Garcia-Palomo, CH Bartlett, M Koehler, R Caballero, M Corsaro, X Huang, JA Garcia-Sáenz, JI Chacón, C Swift, C Thallinger, M Gil-GilFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.